29 Dec 2020
|Title||PharmAbcine, non-confidential slide deck Q4 2020|
PharmAbcine, non-confidential slide deck Q4 2020
Notice of Changes:
- The latest interim results of the ongoing phase Ib olinvacimab+pembrolizumab combo trials in mTNBC patients have been added. In the high-dose cohort, 50% of the patients showed PR (Partial Response), and 67% of the patients received clinical benefits.
- Olinvacimab, the company’s lead asset, will soon undergo an IIT (Investigator-Initiated Trial) in combination with capecitabine, an orally administered anti-cancer drug, in colorectal cancer patients in South Korea to study the efficacy.
- The competitive landscapes of olinvacimab in mTNBC (metastatic Triple-Negative Breast Cancer) and rGBM (recurrent GlioBlastoma Multiforme) have been added in the appendix.
- The key milestones and future events have been updated. Olinvacimab +pembrolizumab phase II combination trial is expected in 1H 2021. PMC-402 is expected to enter a phase I clinical trial in 2021. PMC-403 and PMC-309 are expected to enter a phase I clinical trial in 2022.
Thank you for your continued support.
Please check the attached file for details.